Post-doctoral Fellow - pediatric cancer, tumor microenvironment

Funding Agency:
National Institutes of Health

The McEachron laboratory is seeking a collaborative, highly self-motivated, creative, and productive post-doctoral fellow to join our team.  The laboratory primarily focuses on studying the immune and non-immune microenvironment of pediatric sarcomas, with a particular emphasis on osteosarcoma.  Our goal is to answer challenging, clinically relevant questions using a variety of experimental approaches including spatial transcriptional profiling, functional genomics, DNA/RNA sequencing, multiplexed imaging, in vitro and in vivo model systems, and patient specimens.  Projects include (1) investigating the immunomodulatory effects of specific genomic alterations and the mechanisms by which these alterations function to promote immune escape; and (2) identifying actionable targets that increase the efficacy of immune checkpoint inhibition and adoptive cell therapy in models of metastatic disease.

The McEachron lab is situated within the Pediatric Oncology Branch (POB), located in the NIH Clinical Center.  The POB is a highly collaborative team of basic, translational, and clinical scientists that truly embodies bedside-to-bench and bench-to-beside science.  The collective expertise within the POB, combined with the broad range of educational and technical resources available within the NCI provides a unique and unparalleled training experience.

Agency Website

Eligibility Requirements

The successful candidate will have completed or be approaching the completion of a Ph.D. or M.D.; have a strong background in cancer biology, molecular biology, and/or cellular biology as evidenced by publications in peer-reviewed journals; ability to work independently and as part of a team; and a willingness to learn new skills and cutting-edge technologies.  Proficiency in oral and written English is a must.

Funding Type



Post Doctoral Fellows


Medical - Basic Science
Medical - Clinical Science

External Deadline

May 1, 2021